Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

165

Participants

Timeline

Start Date

September 14, 2017

Primary Completion Date

February 15, 2019

Study Completion Date

May 15, 2019

Conditions
Asthma
Interventions
DRUG

GSK3772847

GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.

DRUG

Placebo

Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.

DRUG

Fluticasone propionate/salmeterol

FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.

DRUG

Fluticasone propionate

FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.

Trial Locations (64)

3004

GSK Investigational Site, Melbourne

3050

GSK Investigational Site, Parkville

3168

GSK Investigational Site, Clayton

5011

GSK Investigational Site, Woodville South

14050

GSK Investigational Site, México DF

14642

GSK Investigational Site, Rochester

15213

GSK Investigational Site, Pittsburgh

21224

GSK Investigational Site, Baltimore

23188

GSK Investigational Site, Williamsburg

28117

GSK Investigational Site, Mooresville

28277

GSK Investigational Site, Charlotte

30103

GSK Investigational Site, Adairsville

32789

GSK Investigational Site, Winter Park

33012

GSK Investigational Site, Hialeah

33134

GSK Investigational Site, Coral Gables

GSK Investigational Site, Miami

33135

GSK Investigational Site, Miami

33144

GSK Investigational Site, Miami

33174

GSK Investigational Site, Miami

33175

GSK Investigational Site, Miami

33185

GSK Investigational Site, Miami

33186

GSK Investigational Site, Miami

35209

GSK Investigational Site, Birmingham

35768

GSK Investigational Site, Scottsboro

43617

GSK Investigational Site, Toledo

44100

GSK Investigational Site, Guadalajara

45231

GSK Investigational Site, Cincinnati

53792

GSK Investigational Site, Madison

62290

GSK Investigational Site, Cuernavaca

63108

GSK Investigational Site, St Louis

64060

GSK Investigational Site, Monterrey

74136

GSK Investigational Site, Tulsa

78006

GSK Investigational Site, Boerne

86035

GSK Investigational Site, Villahermosa

90017

GSK Investigational Site, Los Angeles

90806

GSK Investigational Site, Long Beach

92663

GSK Investigational Site, Newport Beach

93301

GSK Investigational Site, Bakersfield

97070

GSK Investigational Site, Mérida

97504

GSK Investigational Site, Medford

194356

GSK Investigational Site, Saint Petersburg

195067

GSK Investigational Site, Saint Petersburg

198328

GSK Investigational Site, Saint Petersburg

432063

GSK Investigational Site, Ulyanovsk

443068

GSK Investigational Site, Samara

454106

GSK Investigational Site, Chelyabinsk

634028

GSK Investigational Site, Tomsk

650000

GSK Investigational Site, Kemerovo

06510

GSK Investigational Site, New Haven

48109-5360

GSK Investigational Site, Ann Arbor

27599-7248

GSK Investigational Site, Chapel Hill

T8H 0N2

GSK Investigational Site, Sherwood Park

V5Z 1M9

GSK Investigational Site, Vancouver

V6Z 1Y6

GSK Investigational Site, Vancouver

L8N 3Z5

GSK Investigational Site, Hamilton

K1G 6C6

GSK Investigational Site, Ottawa

H2X 3E4

GSK Investigational Site, Montreal

H4A 3J1

GSK Investigational Site, Montreal

G8T 7A1

GSK Investigational Site, Trois-Rivières

G1V 4G5

GSK Investigational Site, Québec

03100

GSK Investigational Site, Mexico City

02002

GSK Investigational Site, Kyiv

02091

GSK Investigational Site, Kyiv

03049

GSK Investigational Site, Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT03207243 - Efficacy and Safety Study of GSK3772847 in Subjects With Moderately Severe Asthma | Biotech Hunter | Biotech Hunter